Previous close | 0.7012 |
Open | 0.6900 |
Bid | 0.6895 x 200 |
Ask | 0.7068 x 100 |
Day's range | 0.6894 - 0.7127 |
52-week range | 0.6710 - 5.9500 |
Volume | |
Avg. volume | 1,366,538 |
Market cap | 28.881M |
Beta (5Y monthly) | 2.53 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Spruce Biosciences (SPRB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
The latest analyst coverage could presage a bad day for Spruce Biosciences, Inc. ( NASDAQ:SPRB ), with the analysts...
Spruce Biosciences' (SPRB) CAHmelia-203 phase IIb study of tildacerfont in adult patients with CAH fails to meet the primary efficacy endpoint.